

Reproductive Health

Group leader

Calaf Alsina, Joaquim (UAB)

Researchers

Coma Barbara, Marina (FGS)
Estadella Tarriel, Josep Ramon (FGS)
Guinot Gasull, Misericordia (FGS)
Mayordomo Bofill, Isabet (FGS)
Miarons Ferré, Bruna (FGS)
Muro Blanc, Patricia (FGS)
Perelló Capo, Josep (FGS)



DESCRIPTION

Gender health is determined by the hormonal regulation of the reproductive system, which affects any organ with hormonal receptors.

Thus, its disturbances, either by excess, defect or dysregulation, also have systemic effects. The group aims to identify the consequences of these abnormalities and to determine the most effective treatment alternatives.

Moreover, menstruating persons periodically face a bleeding event that is not always healthy and friendly. Consequently, measures to modify its profile towards a milder impact on quality of life are welcome.

Our purpose is also to generate tools to identify abnormal patterns and alternatives to surgery to minimise its impact on health.

MAIN LINES OF RESEARCH

- Identification of menstrual abnormalities in the population.
- Effects of environment on menstrual characteristics.
- The medical approach to organic causes of heavy menstrual bleeding
- Menstrual pattern with the different contraceptive alternatives
- Premature ovarian insufficiency its effects, and prevention
- Validate and disseminate a simple, sensitive and reproducible test to identify heavy menstrual bleeding and its response to treatment.



- Test efficient evidence-based approaches to minimise the effect of adnexectomy in BRCA mutation carriers.
- Identify the best contraceptive alternatives for sufferers of chronic menstrual disturbances.
- Vannuccini S, Petraglia F, Carmona F, Calaf J, Chapron C. The modern management of uterine fibroids-related abnormal uterine bleeding. FERTILITY AND STERILITY. 2024; 122(1). DOI:10.1016/j.fertnstert.2024.04.041. PMID:38723935. IF:6,600 (Q1/1D). Document type: Article.

SCIENTIFIC PRODUCTION

- Calaf J, Perelló J, Gich I, Lete I, Novalbos J, Menscovid GRP. Effects of SARS-COVID-19 lockdown on menstrual patterns: A transversal large sample survey. MEDICINA CLINICA. 2024; 162(12). DOI:10.1016/j. medcli.2024.01.016. PMID:38614906. IF:2,600 (Q1/3D). Document type: Article.
- Conde JCQ, Ribes IP, Perelló J, Abascal PL, García IC, García MA, Alés JG, Conde MH, Tarruella JR, Lafuente BE. Costeffectiveness analysis of levonorgestrel releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE. 2024; 29(5). DOI:10.1080/13625187.2024.2369843. PMID:38989683. IF:1,900 (Q3/6D). Document type: Article.
- Perelló J, Estadella J, Gich I, Bailón M, Llurba E, Calaf J. Health-related quality of life and satisfaction associated with 3-year use of a levonorgestrel 13.5 mg intrauterine device vs Nova T copper 380 mm2 intrauterine device: Results of a phase 4 randomized controlled trial. CONTRACEPTION. 2024; 133:110367. DOI:10.1016/j.contraception.2024.110367. PMID:38232939. IF:2,800 (Q1/3D). Document type: Article.
- Perelló J, Rius J, Alsina JC. Linguistic
 Validation of a British-English Version of the
 SAMANTA Questionnaire and HMB-VAS
 Tool: A Step Toward Improved Diagnosis
 of Heavy Menstrual Bleeding. WOMENS
 HEALTH REPORTS. 2024; 5(1). DOI:10.1089/
 whr.2024.0061. PMID:39758525. Document
 type: Article.